New version of ovarian cancer drug tested for safety and effectiveness
NCT ID NCT07371104
First seen Jan 28, 2026 · Last updated May 11, 2026 · Updated 12 times
Summary
This study tests whether a new version of the drug olaparib (DWZ2501) works the same as the current version (DWC202510) in women with advanced BRCA-mutated ovarian cancer. About 40 participants will take both versions at different times to compare drug levels and side effects. The goal is to confirm the new version is a safe and effective alternative for ongoing cancer control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institutional Review Board of Seoul National University Hospital
RECRUITINGSeoul, Jongno-gu, 03080, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.